— Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a third-quarter 2019 loss of $0.21 per share versus a loss of $0.15 per share expected.
— Revenue plunged by 39% to $230,000 versus $50,000 expected. The top line was hurt by nil contract revenue.
— Research and development expenses soared by 59% due to the manufacturing of voclosporin for commercial and investigational use. It also includes costs related to the Aurora 2 extension study and other expenses.
— As looking forward to results from the Aurora Phase 3 trial for kidney inflammation lupus nephritis by the end of this year, the company has been preparing for success by continuing to strengthen the Board.
— Looking ahead to 2020, and assuming positive results, Aurinia plans on submitting an NDA in the first half of 2020 and projects a commercial launch of voclosporin in early 2021 as a potential first-line treatment for lupus nephritis.
Most Popular
Earnings Preview: What to look for when Netflix (NFLX) reports Q4 2025 results
Netflix, Inc. (NASDAQ: NFLX) is expected to report Q4 results on January 20, amid expectations for strong revenue and earnings growth. The company is navigating a shifting streaming landscape where
What to look for when United Airlines (UAL) reports its Q4 2025 earnings results
Shares of United Airlines (NASDAQ: UAL) stayed red on Thursday. The stock has gained 15% over the past three months. The airline is scheduled to report its earnings results for
Infographic: How Constellation Brands (STZ) performed in Q3 2026
Constellation Brands, Inc. (NYSE: STZ) reported net sales of $2.22 billion for the third quarter of 2026, down 10% year-over-year. Organic net sales were down 2%. Net income attributable to
